Utility

1. Utility 9.4.2012 Patent Law Prof Merges

2. Utility – Section 101 Whoever invents and new AND USEFUL machine, manufacture, . . .

3. Main Trouble Areas • No known utility (“perpetual motion machines”) • Newman v. Quigg, 877 F.2d 1575 [ 11 USPQ2d 1340] (Fed. Cir. 1989) (claims to a perpetual motion machine ruled inoperable) • Malicious utility • a "useful" invention is one "which may be applied to a beneficial use in society, in contradistinction to an invention injurious to the morals, health, or good order of society, or frivolous and insignificant"

4. Third major trouble area • Chemical, pharmaceutical, and biotech-related inventions • Why? The nature of chemistry-related research • Structures (molecules) and their uses . . .

5. Justice Story View • Appendix, Note on the Patent Laws, 3 Wheat. 13, 24. See also Justice Story's decisions on circuit in Lowell v. Lewis, 15 Fed. Cas. 1018 (No. 8568) (C. C. D. Mass.), and Bedford v. Hunt, 3 Fed Cas. 37 (No. 1217) (C. C. D. Mass.).

6. Brenner v Manson (Supreme Court 1966) This is not to say that we mean to disparage the importance of contributions to the fund of scientific information short of the invention of something "useful," or that we are blind to the prospect that what now seems without "use" may tomorrow command the grateful attention of the public.

7. Brenner, cont’d • But a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion. "[A] patent system must be related to the world of commerce rather than to the realm of philosophy. * * *"

8. In re Brana 51 F.3d 1560 C.A.Fed. 1995

9. Brana, cont’d

10. R1-R4: Markush groups N: Markush group

11. Brana cont’d • FDA approval, however, is not a prerequisite for finding a compound useful within the meaning of the patent laws. Usefulness in patent law, and in particular in the context of pharmaceutical inventions, necessarily includes the expectation of further research and development.. Were we to require Phase II testing in order to prove utility, the associated costs would prevent many companies from obtaining patent protection on promising new inventions, thereby eliminating an incentive to pursue, through research and development, potential cures in many crucial areas such as the treatment of cancer.

12. Working Model or Prototype; in vivo effectiveness Promising Experimental Results: Brenner v. Manson Promising Clinical Results, e.g., in vitro – In re Brana Project Initiation: Pure Concept Stage

13. In re ‘318 Patent Litigation • 518 F3d 1317 (Fed Cir 2009) • Distnguishing Brana • Only a suggestion to do animal testing, and evidence of in vitro results from a structurally similar compound

14. [N]either in vitro test results nor animal test results involving the use of galantamine to treat Alzheimer's-like conditions were provided. The results from the ′318 patent's proposed animal tests of galantamine for treating symptoms of Alzheimer's disease were not available at the time of the application, and the district court properly held that they could not be used to establish enablement. – 583 F.3d at 1324

15. The Oklahoma Land Rush – A Good Use of Resources?

18. Mining Claim Systems: Require-ments and Timing Issues

19. Some quick economics Terry L. Anderson & Peter J. Hill, The Race for Property Rights, 33 J.L. & Econ. 177 (1990) David D. Haddock, First Possession Versus Optimal Timing: Limiting the Dissipation of Economic Value, 64 Wash. U. L.Q. 775 (1986). Dean Lueck, The Rule of First Possession and the Design of the Law, 38 J.L. & Econ. 393 (1995)

20. Ex Parte Fischer • Major case involving “expressed sequence tags” • Utility the key issue: did inventors demonstrate patentable utility as of the filing date of the patent?

21. Fischer claim 1: p. 241 A substantially purified nucleic acid molecule that encodes a maize protein or fragment thereof comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 5.

22. Ex Parte Fischer • Claim 1, Casebook p. 241 • “Substantially purified” – echoes of Parke-Davis • “Selected from the group consisting of . . .” • What is this claim form?

23. “An article of clothing, selected from the group consisting of Shirts Shoes Pants” “A chemical entity selected from the group consisting of Carbon COOH CH(6)” Markush Group

24. Expressed Sequence Tags Most DNA: Unknown Function EST: Short “Tag” The good stuff: DNA that codes for a protein

25. Multiple Biotechnology Patents: SNP/EST Example A Owns SNP_1 (Or EST_1) B Owns SNP_2/EST_2 C Owns SNP_3/EST_3

26. Fischer • What utilities are claimed? – P. 3 • “determining a relationship between a polymorphism and a plant trait” • “isolating a genetic region . . . Or mapping” • “determining [protein] levels . . .”

27. Fischer - holding • P 22 • Immediate utility is to conduct further experiments • Too attenuated under Brenner and Brana

28. “Expressed Sequence Tag” Patents: policy issues • Bad Idea! Eisenberg & Merges opinion letter, 1995 • Patent law’s “utility requirement” bars these patents • Why? “Capturing someone else’s investment” dominates incentive motive;Transaction Costs a Major Issue

29. Transaction Costs B C A Firm E End Product

30. Transaction Costs II B A C End Product End Product End Product

31. Capturing Someone Else’s Investment • Disproportionate reward • The Proportionality Principle in IP Law